SUMMIT THERAPEU/S (NASDAQ:SMMT)‘s stock had its “hold” rating reaffirmed by equities research analysts at Oppenheimer in a research note issued to investors on Thursday.
SMMT has been the topic of a number of other research reports. ValuEngine upgraded SUMMIT THERAPEU/S from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 20th. Zacks Investment Research upgraded SUMMIT THERAPEU/S from a “strong sell” rating to a “buy” rating and set a $1.50 price target on the stock in a research note on Tuesday, February 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. SUMMIT THERAPEU/S currently has a consensus rating of “Hold” and an average target price of $6.92.
SMMT opened at $1.30 on Thursday. SUMMIT THERAPEU/S has a one year low of $1.10 and a one year high of $14.29. The stock has a market capitalization of $18.55 million, a PE ratio of -1.73 and a beta of 1.19.
SUMMIT THERAPEU/S (NASDAQ:SMMT) last released its quarterly earnings data on Tuesday, December 11th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.50). SUMMIT THERAPEU/S had a net margin of 0.37% and a return on equity of 1.16%. The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.19 million. As a group, sell-side analysts forecast that SUMMIT THERAPEU/S will post 0.91 earnings per share for the current year.
A hedge fund recently raised its stake in SUMMIT THERAPEU/S stock. Acadian Asset Management LLC boosted its stake in shares of SUMMIT THERAPEU/S (NASDAQ:SMMT) by 5.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,160 shares of the company’s stock after acquiring an additional 10,208 shares during the quarter. Acadian Asset Management LLC owned about 1.32% of SUMMIT THERAPEU/S worth $210,000 as of its most recent filing with the Securities and Exchange Commission. 20.91% of the stock is owned by institutional investors and hedge funds.
About SUMMIT THERAPEU/S
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Recommended Story: Outstanding Shares
Receive News & Ratings for SUMMIT THERAPEU/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SUMMIT THERAPEU/S and related companies with MarketBeat.com's FREE daily email newsletter.